AbbVie Partner Spotlight

Featured

Sponsored by AbbVie Medical Affairs
psoriatic arthritis
Sponsored by AbbVie Medical Affairs
The Role of a Selective IL-23 p19 Inhibitor for Patients With Psoriatic Arthritis
06/23/2022
JUNE 23, 2022 Risankizumab (RZB) was approved in April 2019 for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and was approved in...
06/23/2022

Articles

Sponsored by AbbVie Medical Affairs
Rheumatoid Arthritis
Sponsored by AbbVie Medical Affairs
A JAK Inhibitor in Difficult-to-Treat Patients With RA
03/11/2022
Treatment goals can be challenging for those with RA who are bDMARD-IR. Hear Dr. Tesser’s approach and learn about SELECT-BEYOND, where a JAK inhibitor was assessed in such patients.
03/11/2022
Sponsored by AbbVie Medical Affairs
The Science of a JAK Inhibitor in Psoriatic Arthritis
Sponsored by AbbVie Medical Affairs
The Science of a JAK Inhibitor in Psoriatic Arthritis
05/04/2022
Many patients with PsA cannot achieve comprehensive control of their symptoms, despite a variety of available treatments. Learn more about an available JAK inhibitor along with findings from the two phase 3...
05/04/2022